High affinity HIV T cell receptors
US9255135B2 · kind B2 · utility
5Cited by
0References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 3, 2013 |
| Grant date | Feb 9, 2016 |
| Priority date | — |
| Expiry date | Feb 7, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 μM and/or an off-rate (koff) of 1×10−3 S−1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.